• 1
    Barocas DA, Penson DF. Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. BJU Int. 2010;106:322328.
  • 2
    Morris CR, Snipes KP, Schlag R, Wright WE. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Cancer Causes Control. 1999;10:503511.
  • 3
    Schymura MJ, Kahn AR, German RR, et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer. 2010;10:152.
  • 4
    Spencer BA, Miller DC, Litwin MS, et al. Variations in quality of care for men with early-stage prostate cancer. J Clin Oncol. 2008;26:37353742.
  • 5
    Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004;64:11711176.
  • 6
    Carson AP, Howard DL, Carpenter WR, et al. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer. J Pain Symptom Manage. 2010;39:872881.
  • 7
    Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363:18221832.
  • 8
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Fort Washington, PA; National Comprehensive Cancer Network; 2010.
  • 9
    Wilt TJ, Shamliyan T, Taylor B, et al. Comparative effectiveness of therapies for clinically localized prostate cancer. Comparative Effectiveness Review No. 13. Rockville, MD: Agency for Healthcare Research and Quality; February 2008.
  • 10
    National Comprehensive Cancer Network. Prostate Cancer. In: NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA; National Comprehensive Cancer Network; 2004.
  • 11
    Andersen RM, Davidson PL, Ganz PA. Symbiotic relationships of quality of life, health services research and other health research. Qual Life Res. 1994;3:365371.
  • 12
    Sadetsky N, Lubeck DP, Latini DM, et al. Demographics, insurance coverage, and utilization of medical services in newly diagnosed prostate cancer: data from caPSURE. Manag Care Interface. 2005;18:2530.
  • 13
    Talcott JA, Spain P, Clark JA, et al. Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer. 2007;109:15991606.
  • 14
    Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008;58:931.
  • 15
    Schroeder JC, Bensen JT, Su LJ, et al. The North Carolina-Louisiana Prostate Cancer Project (PCaP): methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes. Prostate. 2006;66:11621176.
  • 16
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373383.
  • 17
    LaVeist TA, Nickerson KJ, Bowie JV. Attitudes about racism, medical mistrust, and satisfaction with care among African American and white cardiac patients. Med Care Res Rev. 2000;57(suppl 1):146161.
  • 18
    LaVeist TA, Isaac LA, Williams KP. Mistrust of health care organizations is associated with underutilization of health services. Health Serv Res. 2009;44:20932105.
  • 19
    Stata/IC 11.2 for Windows [computer program]. College Station, TX: StataCorp LP; 2011.
  • 20
    Gross CP, Smith BD, Wolf E, Andersen M. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer. 2008;112:900908.
  • 21
    Chen RC, Carpenter WR, Hendrix LH, et al. Racial Differences in receipt of guideline-recommended treatment in men with low-, intermediate-, and high-risk prostate cancer, a population-based study. American Society of Clinical Oncology. Chicago, IL. J Clin Oncol. 2010:abstr 9002.
  • 22
    D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821827.
  • 23
    Conti PD, Atallah AN, Arruda H, Soares BG, El Dib RP, Wilt TJ. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev. 2007;(4):CD005009.
  • 24
    Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:11171123.
  • 25
    Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law 108-173. 108th Congress (2003).
  • 26
    Dinan MA, Robinson TJ, Zagar TM, et al. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys. 2012;82:e781e786.
  • 27
    Bahnson RR, Hanks GE, Huben RP, et al; National Comprehensive Cancer Network. NCCN practice guidelines for prostate cancer. Oncology (Williston Park). 2000;14:111119.
  • 28
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006;98:839845.
  • 29
    Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol. 2007;25:53595365.
  • 30
    Institute of Medicine, Committee on Cancer Research Among Minorities and the Medically Underserved. The Unequal Burden of Cancer: An Assessment of NIH Research and Programs for Ethnic Minorities and the Medically Underserved. Washington, DC: The National Academies Press; 1999.
  • 31
    State Center for Health Statistics and Office of Minority Health and Health Disparities. North Carolina Minority Health Facts: 2005. African Americans. Raleigh, NC: Department of Health and Human Services; 2005.
  • 32
    Sarrazin MS, Campbell ME, Richardson KK, Rosenthal GE. Racial segregation and disparities in health care delivery: conceptual model and empirical assessment. Health Serv Res. 2009;44:14241444.
  • 33
    Jayadevappa R, Malkowicz SB, Chhatre S, Gallo J, Schwartz JS. Racial and ethnic variation in health resource use and cost for prostate cancer. BJU Int. 2010;106:801808.
  • 34
    Parsons JK, Kwan L, Connor SE, Miller DC, Litwin MS. Prostate cancer treatment for economically disadvantaged men: a comparison of county hospitals and private providers. Cancer. 2010;116:13781384.